Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia

Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia

Intravenous regional anesthesia or the Bier block technique is used to anesthetize a specific limb or extremity. It uses exsanguinated or blood-drained vessels to transport local anesthetics or LAs to the peripheral nerve trunks. Lidocaine without vasoconstrictors like epinephrine is most commonly used for this technique. Other drugs used are prilocaine, ropivacaine, and chloroprocaine. Bupivacaine is not recommended for this technique due to its high cardiac toxicity.
One of the advantages of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HER2 expression and <i>HER2</i> gene amplification in thymic epithelial tumors: a narrative review.

Mediastinum (Hong Kong, China)·2026

Same author

[Non-small cell lung cancer - surgical treatment options in the early stages].

Deutsche medizinische Wochenschrift (1946)·2026

Same author

Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysis.

ERJ open research·2026

Same author

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS).

Journal of cancer research and clinical oncology·2026

Same author

Journal of Thoracic Oncology 20th Anniversary Series Surgery.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Locoregional therapy.

Paul E Van Schil¹, Markus Furrer, Godehard Friedel

¹Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Belgium. paul.van.schil@uza.be

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer

|May 27, 2010

Summary

This summary is machine-generated.

Isolated lung perfusion (ILuP) offers a promising method for delivering high-dose chemotherapy to treat lung metastases, minimizing systemic toxicity. This technique shows superior survival benefits in preclinical models and is feasible in human studies.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Area of Science:

Surgical Oncology
Thoracic Surgery
Pharmacology

Background:

Pulmonary metastases often recur post-resection despite chemotherapy.
Systemic chemotherapy dosage is limited by toxicity.
Lung-sparing subsequent surgeries require sufficient remaining lung parenchyma.

Purpose of the Study:

To explore novel treatment strategies for recurrent pulmonary metastases.
To evaluate the efficacy and safety of isolated lung perfusion (ILuP) for delivering high-dose chemotherapy.
To assess the potential of ILuP with biologic response modifiers.

Main Methods:

Isolated lung perfusion (ILuP) technique for targeted chemotherapy delivery.
Administration of high-dose chemotherapy and biologic response modifiers (e.g., tumor necrosis factor).
Comparison with systemic treatment in experimental models and Phase I human studies.

Main Results:

ILuP demonstrated superior survival advantage over systemic treatment in experimental models.
Significantly higher lung drug concentrations were achieved with ILuP versus intravenous therapy.
Phase I human studies confirmed ILuP's technical feasibility, low morbidity, and preservation of pulmonary function.

Conclusions:

ILuP is a feasible and potentially effective strategy for treating pulmonary metastases.
High-dose chemotherapy via ILuP offers targeted delivery with reduced systemic toxicity.
Further clinical trials are needed to confirm long-term outcomes, including local recurrence, toxicity, and survival.